Sandoz Wants the Rest of Systemix
Do biotech's investors win when a large drug company buys a majority share as opposed to the whole banana? Not usually. Here we've charted the share prices at which acquirors bought shares in their majority owned affiliates, Sandoz's unsolicited bidto buy the rest of SyStemix for $17 a share represents an enormous let-down for investors.
You may also be interested in...
TransEnterix hires Shameze Rampertab as its new CFO and said it expects “modest growth” in Q3 and Q4.
Keeping Track: Viltepso Earns Priority Review Voucher; Manufacturing Trips Fennec; Eagle Drops Ryanodex Exertional Heat Stroke Bid
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.
CureVac raised hundreds of millions of dollars this year before its $213m initial public offering as its mRNA vaccine technology moved into the COVID-19 spotlight. Its stock price tripled on its debut.